FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4382181350> ?p ?o ?g. }

• W4382181350 abstract "Abstract Background Even though cytoreductive nephrectomy (CN) was once the standard of care for patients with advanced renal cell carcinoma (RCC), its role in treatment has not been well analyzed or defined in the era of immunotherapy (IO). Materials and Methods This study analyzed pathological outcomes in patients with advanced or metastatic RCC who received IO prior to CN. This was a multi-institutional, retrospective study of patients with advanced or metastatic RCC. Patients were required to receive IO monotherapy or combination therapy prior to radical or partial CN. The primary endpoint assessed surgical pathologic outcomes, including American Joint Committee on Cancer (AJCC) staging and frequency of downstaging, at the time of surgery. Pathologic outcomes were correlated to clinical variables using a Wald-chi squared test from Cox regression in a multi-variable analysis. Secondary outcomes included objective response rate (ORR) defined by response evaluation criteria in solid tumors (RECIST) version 1.1 and progression-free survival (PFS), which were estimated using the Kaplan-Meier method with reported 95% CIs. Results Fifty-two patients from 9 sites were included. Most patients were male (65%), 81% had clear cell histology, 11% had sarcomatoid differentiation. Overall, 44% of patients experienced pathologic downstaging, and 13% had a complete pathologic response. The ORR immediately prior to nephrectomy was stable disease in 29% of patients, partial response in 63%, progressive disease in 4%, and 4% unknown. Median follow-up for the entire cohort was 25.3 months and median PFS was 3.5 years (95% CI, 2.1-4.9). Conclusions IO-based interventions prior to CN in patients with advanced or metastatic RCC demonstrates efficacy, with a small fraction of patients showing a complete response. Additional prospective studies are warranted to investigate the role of CN in the modern IO-era." @default.
• W4382181350 created "2023-06-28" @default.
• W4382181350 creator A5010702339 @default.
• W4382181350 creator A5012770348 @default.
• W4382181350 creator A5016482213 @default.
• W4382181350 creator A5018399405 @default.
• W4382181350 creator A5020223699 @default.
• W4382181350 creator A5020896608 @default.
• W4382181350 creator A5023117975 @default.
• W4382181350 creator A5023616396 @default.
• W4382181350 creator A5028897583 @default.
• W4382181350 creator A5030296245 @default.
• W4382181350 creator A5032481550 @default.
• W4382181350 creator A5033486347 @default.
• W4382181350 creator A5036202423 @default.
• W4382181350 creator A5046795494 @default.
• W4382181350 creator A5050769182 @default.
• W4382181350 creator A5053588971 @default.
• W4382181350 creator A5057146540 @default.
• W4382181350 creator A5058325420 @default.
• W4382181350 creator A5062640845 @default.
• W4382181350 creator A5071666691 @default.
• W4382181350 creator A5074723981 @default.
• W4382181350 creator A5081597269 @default.
• W4382181350 creator A5081652595 @default.
• W4382181350 creator A5085399720 @default.
• W4382181350 creator A5089109606 @default.
• W4382181350 creator A5091070593 @default.
• W4382181350 creator A5091129809 @default.
• W4382181350 creator A5091807397 @default.
• W4382181350 date "2023-06-27" @default.
• W4382181350 modified "2023-09-23" @default.
• W4382181350 title "Pathological Outcomes of Patients With Advanced Renal Cell Carcinoma Who Receive Nephrectomy Following Immunotherapy" @default.
• W4382181350 cites W2021256410 @default.
• W4382181350 cites W2072478300 @default.
• W4382181350 cites W2520690676 @default.
• W4382181350 cites W2791504329 @default.
• W4382181350 cites W2792937256 @default.
• W4382181350 cites W2801460366 @default.
• W4382181350 cites W2805060661 @default.
• W4382181350 cites W2894584497 @default.
• W4382181350 cites W2899539231 @default.
• W4382181350 cites W2901702371 @default.
• W4382181350 cites W2904657085 @default.
• W4382181350 cites W2904734158 @default.
• W4382181350 cites W2911812451 @default.
• W4382181350 cites W2916647762 @default.
• W4382181350 cites W2939049629 @default.
• W4382181350 cites W2958452986 @default.
• W4382181350 cites W2972960135 @default.
• W4382181350 cites W2976943443 @default.
• W4382181350 cites W2982617740 @default.
• W4382181350 cites W2991382799 @default.
• W4382181350 cites W3007447088 @default.
• W4382181350 cites W3014615279 @default.
• W4382181350 cites W3029490475 @default.
• W4382181350 cites W3034060110 @default.
• W4382181350 cites W3034067524 @default.
• W4382181350 cites W3093923068 @default.
• W4382181350 cites W3120396292 @default.
• W4382181350 cites W3131063362 @default.
• W4382181350 cites W3133932842 @default.
• W4382181350 cites W3162250788 @default.
• W4382181350 cites W3184405991 @default.
• W4382181350 cites W3206947483 @default.
• W4382181350 cites W4206841660 @default.
• W4382181350 cites W4212773757 @default.
• W4382181350 cites W4229029457 @default.
• W4382181350 cites W4285679063 @default.
• W4382181350 cites W4306955734 @default.
• W4382181350 doi "https://doi.org/10.1093/oncolo/oyad166" @default.
• W4382181350 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37368355" @default.
• W4382181350 hasPublicationYear "2023" @default.
• W4382181350 type Work @default.
• W4382181350 citedByCount "0" @default.
• W4382181350 crossrefType "journal-article" @default.
• W4382181350 hasAuthorship W4382181350A5010702339 @default.
• W4382181350 hasAuthorship W4382181350A5012770348 @default.
• W4382181350 hasAuthorship W4382181350A5016482213 @default.
• W4382181350 hasAuthorship W4382181350A5018399405 @default.
• W4382181350 hasAuthorship W4382181350A5020223699 @default.
• W4382181350 hasAuthorship W4382181350A5020896608 @default.
• W4382181350 hasAuthorship W4382181350A5023117975 @default.
• W4382181350 hasAuthorship W4382181350A5023616396 @default.
• W4382181350 hasAuthorship W4382181350A5028897583 @default.
• W4382181350 hasAuthorship W4382181350A5030296245 @default.
• W4382181350 hasAuthorship W4382181350A5032481550 @default.
• W4382181350 hasAuthorship W4382181350A5033486347 @default.
• W4382181350 hasAuthorship W4382181350A5036202423 @default.
• W4382181350 hasAuthorship W4382181350A5046795494 @default.
• W4382181350 hasAuthorship W4382181350A5050769182 @default.
• W4382181350 hasAuthorship W4382181350A5053588971 @default.
• W4382181350 hasAuthorship W4382181350A5057146540 @default.
• W4382181350 hasAuthorship W4382181350A5058325420 @default.
• W4382181350 hasAuthorship W4382181350A5062640845 @default.
• W4382181350 hasAuthorship W4382181350A5071666691 @default.
• W4382181350 hasAuthorship W4382181350A5074723981 @default.
• W4382181350 hasAuthorship W4382181350A5081597269 @default.
• W4382181350 hasAuthorship W4382181350A5081652595 @default.
• W4382181350 hasAuthorship W4382181350A5085399720 @default.

• next